Lymphoseek tilmanocept regulatory update

On Dec. 17, 2013, Navidea said it submitted an sNDA for Lymphoseek tilmanocept for sentinel lymph node detection in patients with head and neck cancer. Lymphoseek has Fast Track designation for the indication. Navidea and Cardinal Health Inc. (NYSE:CAH, Dublin, Ohio) launched the product in the U.S. last May for use in intraoperative lymphatic imaging in breast cancer and melanoma patients (see BioCentury, May 6, 2013). ...